The oncogenic potential of variant, AR-V7 was further demonstrated by a study showing that combined AR-FL and AR-V7 degradation by inhibitors of a de-ubiquitinase, USP7, reduced the proliferative activity of PCa cells [81], thus advocating the role of AR-Vs in cancer progression. This evidence concerns the gene AR and cancer.